3-(2-Ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy} phenyl)propanoic acid: A brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGluR2)

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 9, 2005, Pages 2389-2393

  Cube, Rowena V ^a   Vernier, Jean Michel ^a   Hutchinson, John H ^a   Gardner, Michael F ^a   James, Joyce K ^a   Rowe, Blake A ^a   Schaffhauser, Herve ^a   Daggett, Lorrie ^a   Pinkerton, Anthony B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Allosteric modulator; Coumarin; Glutamate; mGluR2; Potentiator; Tetrazole

Indexed keywords

GLUTAMATE RECEPTOR 2; METABOTROPIC RECEPTOR AGONIST; PROPIONIC ACID DERIVATIVE;

ALLOSTERISM; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG IDENTIFICATION; DRUG PENETRATION; DRUG POTENCY; DRUG SYNTHESIS; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

EID: 17144417749     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.02.078     Document Type: Article

References (23)

1. P.J. Conn, and J.P. Pin Annu. Rev. Pharmacol. Toxicol. 37 1997 205
2. D.D. Schoepp, D.E. Jane, and J.A. Monn Neuropharmacology 38 1999 1431
3. A.G. Lam, M.A. Soriano, J.A. Monn, D.D. Schoepp, D. Lodge, and J. McCulloch Neurosci. Lett. 254 1998 121
4. A.E. Kingston, M.J. O'Neill, A. Lam, K.R. Bales, J.A. Monn, and D.D. Schoepp Eur. J. Pharmacol. 377 1999 155
5. D.R. Helton, J.P. Tizzano, J.A. Monn, D.D. Schoepp, and M.J. Kallman J. Pharmacol. Exp. Ther. 284 1998 651
6. L.E. Chavez-Noriega, H. Schaffhauser, and U.C. Campbell Curr. Drug Targets 1 2002 261
7. J.A. Monn, M.J. Valli, S.M. Massey, R.A. Wright, C.R. Salhoff, B.G. Johnson, T. Howe, C.A. Alt, G.A. Rhodes, R.L. Robey, K.R. Griffey, J.P. Tizzano, M.J. Kallman, D.R. Helton, and D.D. Schoepp J. Med. Chem. 40 1997 528
8. J.A. Monn, M.J. Valli, S.M. Massey, M.M. Hansen, T.J. Kress, J.P. Wepsiec, A.R. Harkness, J.L. Grutsch Jr., R.A. Wright, B.G. Johnson, S.L. Andis, A. Kingston, R. Tomlinson, R. Lewis, K.R. Griffey, J.P. Tizzano, and D.D. Schoepp J. Med. Chem. 42 1999 1027
9. A. Nakazato, T. Kumagai, K. Sakagami, R. Yoshikawa, Y. Suzuki, S. Chaki, H. Ito, T. Taguchi, S. Nakanishi, and S. Okuyama J. Med. Chem. 43 2000 4893
10. L. Levine, B. Gaydos, D. Sheehan, A.W. Goddarg, J. Feighner, W.Z. Potter, and D.D. Schoepp Neuropharmacology 43 2002 294
11. C. Grillon, J. Cordova, L.R. Levine, and C.A. Morgan III Psychopharmacology 168 2003 446
12. D.D. Schoepp, R.A. Wright, L.R. Levine, B. Gaydos, and W.Z. Potter Stress 6 2003 189
13. F. Knoflach, V. Mutel, S. Jolidon, J.N.C. Kew, P. Malherbe, E. Viera, J. Wichmann, and J.A. Kemp Proc. Natl. Acad. Sci. U.S.A. 98 2001 13402
14. M.P. Johnson, M. Baez, G.E. Jagdmann Jr., T.C. Britton, T.H. Large, D.O. Callagaro, J.P. Tizzano, J.A. Monn, and D.D. Schoepp J. Med. Chem. 46 2003 3189
15. H. Schaffhauser, B.A. Rowe, Chavez-Noriega L.E. Morales, R. Yin, C. Jachec, S.P. Rao, G. Bain, A.B. Pinkerton, J.-M. Vernier, L.J. Bristow, M.A. Varney, and L.P. Daggett Mol. Pharmacol. 64 2003 798
16. 2+ sensitive dye fura-2. For further information, see: M.A. Varney, N.D. Cosford, C. Jachec, S.P. Rao, A. Sacaan, F.F. Lin, L. Bleicher, E.M. Santori, P.J. Flor, H. Allgeier, F. Gasparini, R. Kuhn, S.D. Hess, G. Velicelebi, and E.C. Johnson J. Pharmacol. Exp. Ther. 290 1999 170
17. A.B. Pinkerton, J.-M. Vernier, H. Schaffahuser, B.A. Rowe, U.C. Campbell, D.E. Rodriguez, D.S. Lorrain, C.S. Baccei, L.P. Daggett, and L.J. Bristow J. Med. Chem. 47 2004 4595
18. 50 and a percent potentiation (the response normalized to the maximum response of glutamate alone). The same experiment was carried out in the absence of glutamate to test if the compound was truly a positive allosteric modulator. Non-specific binding was determined by addition of 10 μM unlabeled GTPγS. See Ref. 14 for a detailed description of this assay
19. A.B. Pinkerton, R.V. Cube, J.H. Hutchinson, B.A. Rowe, H. Schaffhauser, X. Zhao, L.P. Daggett, and J.-M. Vernier Bioorg. Med. Chem. Lett. 14 2004 5329
20. A.B. Pinkerton, R.V. Cube, J.H. Hutchinson, Joyce J.K. James, M.F. Gardner, H. Schaffhauser, B.A. Rowe, L.P. Daggett, and J.-M. Vernier Bioorg. Med. Chem. Lett. 14 2004 5867
21. ++Na). HPLC-MS showed greater than 95% purity for compound 8. Strong hydrogen bonding between the phenol proton and the ketone greatly downshifts the phenol proton singlet to 13 ppm, a diagnostic signal in the proton NMR for all of the analogs described herein. This singlet is observed in compound 8. Therefore, we conclude that ethylation occurs regioselectively as specified
22. 1H NMR, HPLC-MS) consistent with the assigned structure (purity >95%)
23. K. Koch, and M.S. Biggers J. Org. Chem. 59 1994 1216